UnfoldIPThemes

Company patents

RNA Therapeutics, Inc.

RNA Therapeutics, Inc. shows a surprising and almost exclusive focus on Peptides & Proteins, which constitutes 87.2% of its patent portfolio and saw an explosive growth of 3900.0% so far in 2026, with 40 patents filed after a complete halt in 2025. This intense concentration contrasts sharply with the declining attention to Pharmaceutical Preparations and Therapeutic Activity (Pharma), which have seen YoY drops of 50.0% and 100.0% respectively in 2026, suggesting a significant strategic pivot towards core peptide and protein innovations.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

47 US filings (since 2023) · 3 categories · 6 themes

Immunomodulatory Protein Design is up +5600.0% YoY. Worth a look.
Antibody Engineering & Therapeutics

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Peptides & ProteinsPharmaceutical Preparations
Who else files here? →
40since 2023
new
Immunomodulatory Protein Design

Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.

Peptides & Proteins
Who else files here? →
30since 2023
+5600.0%YoY
Advanced Cell & Gene Therapies

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Peptides & ProteinsPharmaceutical Preparations
Who else files here? →
3since 2023
0.0%YoY
Nucleic Acid-Based Therapies

Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.

Pharmaceutical Preparations
Who else files here? →
3since 2023
-50.0%YoY
Targeted Drug Formulation Delivery

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Pharmaceutical Preparations
Who else files here? →
2since 2023
+100.0%YoY
Protein & Peptide Engineering

Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.

Peptides & Proteins
Who else files here? →
1since 2023
n/a

Patents

Showing 1-10 of 47

Page 1 of 5
US 20260078174 A1APPLICATION
C07K16/18

SINGLE-CHAIN MEDI1341 ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed:2024-09-16Pub:2026-03-19
Applicant:RNA Therapeutics, Inc.

The efficacy and indication of MEDI1341 do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

US 20260078173 A1APPLICATION
C07K16/18

SINGLE-CHAIN ZAGOTENEMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed:2024-09-16Pub:2026-03-19
Applicant:RNA Therapeutics, Inc.

The efficacy and indication of zagotenemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

US 20260062489 A1APPLICATION
C07K16/28

SINGLE-CHAIN TEPROTUMUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed:2024-08-30Pub:2026-03-05
Applicant:RNA Therapeutics, Inc.

The efficacy and indication of teprotumumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

US 20260062473 A1APPLICATION
C07K16/24

SINGLE-CHAIN TILDRAKIZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed:2024-08-31Pub:2026-03-05
Applicant:RNA Therapeutics, Inc.

The efficacy and indication of tildrakizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

US 20260062468 A1APPLICATION
C07K16/18

SINGLE-CHAIN TILAVONEMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed:2024-08-31Pub:2026-03-05
Applicant:RNA Therapeutics, Inc.

The efficacy and indication of tilavonemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

US 20260062467 A1APPLICATION
C07K16/18

SINGLE-CHAIN SOLANEZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed:2024-08-30Pub:2026-03-05
Applicant:RNA Therapeutics, Inc.

The efficacy and indication of solanezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

US 20260055196 A1APPLICATION
C07K16/28

SINGLE-CHAIN ROMIPLOSTIM ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed:2024-08-22Pub:2026-02-26
Applicant:RNA Therapeutics, Inc.

The efficacy and indication of romiplostim do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

US 20260055175 A1APPLICATION
C07K16/24

SINGLE-CHAIN SECUKINUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed:2024-08-24Pub:2026-02-26
Applicant:RNA Therapeutics, Inc.

The efficacy and indication of secukinumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

US 20260055174 A1APPLICATION
C07K16/24

SINGLE-CHAIN RISANKIZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed:2024-08-22Pub:2026-02-26
Applicant:RNA Therapeutics, Inc.

The efficacy and indication of risankizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

US 20260055170 A1APPLICATION
C07K16/22

SINGLE-CHAIN ROMOSOZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed:2024-08-24Pub:2026-02-26
Applicant:RNA Therapeutics, Inc.

The efficacy and indication of romosozumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

12345